Early Access — free while we kick the tires
EdgarHawk

Vu Quan Anh

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2025-12-29

Never miss a filing from Vu Quan Anh

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Monopar Therapeutics MNPR 1 0 Net buying

Activity

December 2025
2025-12-29 Monopar Therapeutics MNPR
medium
Buy
1,500 shares
$104,925
Significance 6/10

CFO Vu Quan Anh bought 1,500 shares of MNPR at $69.95; stock now at $65.57, down 35.8% from 52-week high

CFO Vu Quan Anh initiated a position of 1,500 shares at $69.95, representing a first-time purchase with no prior holdings. The acquisition occurs against a backdrop of significant stock weakness: the current price of $65.57 sits 35.8% below the 52-week high of $102.05, and the stock has declined 23.9% over the prior 30 days. The company is unprofitable with net income of $-3,437,601.00 over the most recent full fiscal year, and the latest quarter showed zero revenue. This insider buy by a CFO at a substantially depressed valuation—after steep price declines—presents a potential positive signal regarding management's view of intrinsic value, though the underlying fundamental challenges (negative earnings, no recent revenue) remain material constraints on the transaction's significance.

Related insiders